DURAGESIC-75
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DURAGESIC-75 (DURAGESIC-75).
Fentanyl is a potent opioid agonist primarily at the mu-opioid receptor, exerting its analgesic effects by mimicking endogenous endorphins and enkephalins to activate G-protein-coupled inwardly rectifying potassium channels, leading to hyperpolarization and reduced neuronal excitability in pain pathways.
| Metabolism | Primarily metabolized via CYP3A4 in the liver and intestinal mucosa to norfentanyl and other minor metabolites; undergoes extensive first-pass metabolism. |
| Excretion | Renal (75% as metabolites, <10% unchanged), fecal (25%) |
| Half-life | 22-25 hours after removal of patch; increased in elderly, hepatic/renal impairment |
| Protein binding | 90-95% bound to alpha-1-acid glycoprotein and albumin |
| Volume of Distribution | 6-7 L/kg, indicating extensive tissue distribution |
| Bioavailability | Fentanyl transdermal: 50-65% of patch content absorbed into systemic circulation |
| Onset of Action | 12-18 hours after first application for initial analgesia; steady state by 72 hours |
| Duration of Action | 72 hours per patch; continuous release with residual analgesia up to 24 hours after removal |
Adults: Apply one 75 mcg/hr transdermal patch every 72 hours. Start with lower dose in opioid-naive patients.
| Dosage form | FILM, EXTENDED RELEASE |
| Renal impairment | GFR 30-89 mL/min: No adjustment. GFR <30 mL/min: Reduce dose by 50% and monitor. |
| Liver impairment | Child-Pugh Class A: No adjustment. Class B: Reduce dose by 25-50%. Class C: Avoid use. |
| Pediatric use | Children ≥2 years: 12.5-25 mcg/hr initial, titrate based on need; max dose 25 mcg/hr for opioid-naive. |
| Geriatric use | Initial dose reduction of 25-50%; titrate cautiously; avoid in frail elderly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DURAGESIC-75 (DURAGESIC-75).
| Breastfeeding | Fentanyl is excreted in breast milk. M/P ratio approximately 0.4. Breastfeeding is generally not recommended during Duragesic-75 use due to risk of infant sedation and respiratory depression. If used, monitor infant for unusual sleepiness, difficulty breathing, or poor feeding. Alternative analgesics are preferred. |
| Teratogenic Risk | Fetal risk cannot be ruled out. In first trimester, no clear evidence of major malformations from opioid analgesics, but data limited. Second and third trimesters: chronic use may cause fetal opioid dependence, neonatal abstinence syndrome (NAS) postpartum. Use during labor may cause respiratory depression in neonate. Risk of preterm birth and low birth weight with prolonged use. |
■ FDA Black Box Warning
Risk of respiratory depression that may result in death; ensure proper patient selection, dosing, and monitoring. Avoid use in opioid non-tolerant patients. Accidental exposure can be fatal. Concomitant use with CNS depressants increases risk. Risk of abuse, misuse, addiction, and diversion. Neonatal opioid withdrawal syndrome with prolonged use during pregnancy. Risk of life-threatening respiratory depression from CYP3A4 inhibitors or discontinuation of CYP3A4 inducers.
| Serious Effects |
["Opioid non-tolerant patients (not established for acute pain or short-term use)","Significant respiratory depression","Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment","Known or suspected gastrointestinal obstruction, including paralytic ileus","Hypersensitivity to fentanyl or any component of the system (e.g., adhesives)","Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy"]
| Precautions | ["Risk of life-threatening respiratory depression, especially in elderly, cachectic, or debilitated patients","Risk of opioid-induced hyperalgesia","Risk of serotonin syndrome with serotonergic drugs","Hypersensitivity reactions including anaphylaxis","Risk of withdrawal with abrupt discontinuation","Hepatic or renal impairment may alter pharmacokinetics","Avoid in patients with significant respiratory depression, acute or severe bronchial asthma, or known or suspected paralytic ileus","May impair mental or physical abilities needed for driving or operating machinery","Use with caution in patients with head injuries, increased intracranial pressure, or convulsive disorders","Application site reactions or adhesive-related injuries"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal respiratory status (respiratory rate, oxygen saturation) and sedation level. Fetal monitoring: assess fetal heart rate patterns, especially during use in third trimester or labor. Neonatal monitoring for signs of opioid withdrawal (NAS) for at least 48 hours after birth if prolonged maternal use. Liver and renal function tests periodically. |
| Fertility Effects | No specific studies on human fertility. Opioid use may affect hormonal cycles (e.g., decreased libido, menstrual irregularities) in women. In men, may reduce testosterone levels, potentially impacting spermatogenesis. Effects are reversible upon discontinuation. |
| Food/Dietary | No significant food interactions. Grapefruit juice may increase fentanyl levels via CYP3A4 inhibition; caution with high intake. Avoid alcohol due to additive CNS depression. |
| Clinical Pearls | DURAGESIC-75 delivers fentanyl at 75 mcg/hour transdermally. Do not use in opioid-naive patients due to risk of fatal respiratory depression. Apply to non-irritated, non-hairy skin on upper torso or upper arm. Avoid heat sources (heating pads, hot tubs) as heat increases absorption. Onset ~12-24 hours; peak effect ~24-72 hours. Remove old patch before applying new; rotate sites. Do not cut or damage the patch. Monitor for serotonin syndrome if used with serotonergic drugs. For breakthrough pain, use immediate-release opioids not additional fentanyl patches. |
| Patient Advice | Apply the patch to a flat, non-hairy area of the upper body or arm. Do not use on skin that is irritated, cut, or scarred. · Do not expose the patch to direct heat sources like heating pads, electric blankets, hot tubs, or sunbathing—this can cause a dangerous overdose. · Wash hands after handling the patch. Dispose of used patches by folding sticky sides together and flushing down toilet per FDA guidelines. · Remove the old patch and apply the new patch to a different skin site every 72 hours (3 days). Rotate sites to avoid skin irritation. · Do not cut, chew, or damage the patch—this can lead to rapid release of fentanyl and fatal overdose. · Store patches in a secure place away from children and pets. Accidental exposure can be fatal. · Common side effects include nausea, vomiting, constipation, dizziness, and drowsiness. Report severe drowsiness, confusion, difficulty breathing, or signs of an allergic reaction. · Avoid alcohol, other opioids, benzodiazepines, and sedatives as they increase risk of respiratory depression. · Do not stop using this medication suddenly; taper with prescriber to avoid withdrawal symptoms. · Seek emergency care for symptoms of overdose: slow or shallow breathing, extreme drowsiness, or unresponsiveness. |